Navigation Links
Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
Date:5/23/2013

g-standing expert in R&D outsourcing."

"We look forward to working with Cenix, whose specialist expertise, longstanding leadership and unrivaled track record in this field made them an ideal partner," commented Dr. Hiroaki Tanaka , Director of Personalized Medicine, Debiopharm. "The opportunity to benefit from such depth of knowledge, experience and extensively validated capabilities is considered as the most strategically important resource for preclinical biomarkers discovery."

About Cenix BioScience

With operations in Germany, Belgium and the U.S., Cenix BioScience conducts contract research and develops new reagent technologies focused on a wide array of preclinical cell-based and in vivo applications including RNAi-based gene silencing, miRNA modulation, compound testing, advanced genomics analyses and high content screening to accelerate drug discovery and development. Now in its 14th year, Cenix has built up leading scientific and commercial track records, successfully advancing therapeutic programs for numerous top industry and academic partners in a broad range of disease fields. This success, illustrated by a high rate of repeat business from top clients, is anchored in the consistent application of industrial best practices within fully customized, multi-staged projects designed to offer maximal strategic value and accountability with carefully minimized risk and full data transparency. For more information, please visit the company's web site: http://www.cenix.com

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates ha
'/>"/>

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
2. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
3. Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
4. Sangamo BioSciences Reports First Quarter 2013 Financial Results
5. Neurocrine Biosciences Reports First Quarter 2013 Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Register by April 30th to get the Discounted Rate for Association of Bioscience Financial Officers (ABFO) 2013 National Conference - San Diego
8. CytoVas And BD Biosciences Ink Alliance To Co-Develop Personalized Diagnostic For Vascular Health
9. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
10. Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
11. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BERGEN, Norway , September 23, 2014 /PRNewswire/ ... "Company"), an oncology biopharmaceutical company, today announces it ... million) Seeding Drug Discovery Award from the UK,s ... against BGB002, its proprietary, novel cancer target. ... are to identify and fund especially promising, innovative ...
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... additions to its Scientific Advisory Board.  The new members ... Davies , PhD. Dr. Acker is a ...
Breaking Medicine Technology:BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7
... Harco Metal Products (Harco), an industry leader in tube fabrication, systems ... manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products for health ... cost associated with staff injuries caused by physically lifting and moving ...
... 23 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... 26, 2010 , at 8:00 a.m. Eastern Time ( 5:00 ... , , ... live webcast of the presentation on the company,s website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar ...
Cached Medicine Technology:Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib 2
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
(Date:9/23/2014)... Wellesley, Mass., September 23, 2014 – BCC Research ( ... Joint Reconstruction and Replacement: Materials, Technologies, and Global Markets ... is expected to increase to nearly $16.2 billion by ... 4.2% from 2013 through 2018. The U.S. occupies the ... CAGR of 5.1%. , Revision and partial joint replacement ...
(Date:9/23/2014)... eCaring, a leading health care quality ... contract to provide its unique Web-based home health care ... New York City’s largest not-for-profit health plans. Elderplan, an ... to help enhance the care of its Medicare, Medicaid ... Elderplan has been at the forefront of offering New ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... revenue for the Fruit and Vegetable Markets ... consumption and fruit prices benefited operators over the ... industry follow unique preference and demographic trends, including ... US population. While per capita fruit and vegetable ...
(Date:9/23/2014)... the results of their cancer research at ESMO ... Joint Symposium: ESMO-ASCO: The Evolution of the ... AM - 12:30 PM, Room: Granada, Abstract 121IN: ... new forms of cancer clinical research? The example ... Paper session: Melanoma and other skin tumors , ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3
... new study has established the wholesomeness of whole wheat ... breast cancer risk in the offspring.// ,Dr ... her colleagues examined the benefits of dietary changes on ... health. These results could well mimic the occurrence in ...
... health care for patients that was released by the ... countries, except the U.S. ,In the survey ... was found that Canada lagged in several aspects including ... doctors availability after hours, multi-discipline teams for treatment of ...
... to arouse strong feelings either way has been brought up ... the proposal suggests mercy killing of// new borns who are ... Gynaecology put forth this recommendation as the solution to the ... are being kept alive because of the advanced technology ...
... 7 and the theme selected is Cancer and Women. ... on that day// to promote awareness and motivate people ... ,"Run 4 Cancer" will be flagged off by SSP ... Allahabad Division RN Tripathi will preside over a lecture ...
... a biotechnology firm based in Seattle has called off further ... year following the untimely deaths// of few of the patients ... efficacy of the cancer drug Xyotax. ,The CEO of ... the volunteer s who were cancer patients do not seem ...
... raising the retirement age for civil servants from 60 to ... soaring pension bill//. ,Moreover, improving health standards and ... retiring are being cited among the reasons for the move. ... Reforms (NCGR) told The News International that the reform body ...
Cached Medicine News:Health News:Consider Euthanasia For Severely Disabled Babies, College Tells Doctors 2Health News:Awareness about Women's Cancers- A National Concern 2Health News:Multiple deaths forces cancer trial to be called off 2Health News:Pakistan civil servants may retire at 62 2
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
... Featuring new technology, such as a recessed ... and lens housings, this arthroscope has superior ... by EO, Steris and steam autoclaving or ... Light post/adapters to fit ACMI, Wolf, Dyonics ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
Medicine Products: